Pancreatic cancer blood test study pulled before it began

NCT ID NCT05188573

Terminated Diagnosis Sponsor: ClearNote Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if a simple blood test could spot early signs of pancreatic cancer in adults aged 50 and older who were recently diagnosed with type 2 diabetes. The plan was to enroll 10,000 participants and follow up with MRI scans for those with a positive test result. However, the study was withdrawn before any volunteers were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: blood test for pancreatic cancer detection
What this could lead to: If validated, this test could help catch pancreatic cancer earlier in people with new-onset diabetes, potentially improving survival odds.
What could go wrong: The study was withdrawn before any participants enrolled, so no data was collected. The test's real-world accuracy and benefit remain unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEW-ONSET TYPE II DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Bluestar Genomics, Inc.

San Diego, California, 92121, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.